Affymax, Inc. announced that it will retain a bank to evaluate strategic alternatives for the organization, including the sale of the company or its assets, or a corporate merger. Affymax is considering all possible alternatives, including further restructuring activities, wind-down of operations or even bankruptcy proceedings. Affymax announced that it will reduce its workforce by 75% as part of a plan to focus the company's resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving OMONTYS Injection.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +6.67% | 0.00% | +33.33% |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 55.87K | |
+34.26% | 50.85B | |
+0.37% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.94% | 26.11B | |
-21.97% | 19.13B | |
+8.68% | 13.05B | |
+26.99% | 12.16B | |
+24.38% | 12.08B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax Seeks Strategic Alternatives